Literature DB >> 23391370

Human cytomegalovirus infection levels in glioblastoma multiforme are of prognostic value for survival.

Afsar Rahbar1, Abiel Orrego, Inti Peredo, Mensur Dzabic, Nina Wolmer-Solberg, Klas Strååt, Giuseppe Stragliotto, Cecilia Söderberg-Nauclér.   

Abstract

BACKGROUND: Patients with glioblastoma multiforme (GBM) generally live 12-15 months after diagnosis, despite maximal surgical resection, adjuvant radiotherapy, and chemotherapy. HCMV has been detected in 90-100% of GBMs. We recently found that low grade HCMV infection in GBM tumours was highly associated with survival over 18 months (case-control study). Here, we sought to determine whether low-grade HCMV infection in GBMs is associated with prolonged survival in a consecutive patient cohort, analysed retrospectively. STUDY
DESIGN: Tumour samples from 75 consecutive GBM patients treated surgically at Karolinska University Hospital in 2004-2005 were examined by immunohistochemistry (IHC) and in situ hybridization for HCMV proteins and DNA, respectively. Tumours were graded 1-4, depending on the percentage of positive cells by IHC. Low-grade HCMV was defined as grade 1 (< 25% of HCMV infected tumour cells). Time to tumour progression (TTP) and survival data were analysed with Cox regression and Kaplan-Meier models.
RESULTS: HCMV infection was detected in 74 of 75 tumours (99%). In patients with low-grade HCMV infection, median survival was 20 months longer than in patients with high-grade infections (P = 0.036, HR: 2.2), and TTP was 8 months longer (P = 0.1, HR: 1.8). Two-year survival was much higher in patients with low-grade HCMV infection (63.6% vs. 17.2%, P = 0.003).
CONCLUSION: The longer survival in patients whose tumours had low-grade HCMV infection suggests that the level of HCMV infection in GBMs has a prognostic value and that HCMV may contribute to the pathogenesis of GBM.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23391370     DOI: 10.1016/j.jcv.2012.12.018

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  55 in total

1.  Enhanced neutrophil activity is associated with shorter time to tumor progression in glioblastoma patients.

Authors:  Afsar Rahbar; Madeleine Cederarv; Nina Wolmer-Solberg; Charlotte Tammik; Giuseppe Stragliotto; Inti Peredo; Olesja Fornara; Xinling Xu; Mensur Dzabic; Chato Taher; Petra Skarman; Cecilia Söderberg-Nauclér
Journal:  Oncoimmunology       Date:  2015-08-24       Impact factor: 8.110

2.  Response to "Human cytomegalovirus infection in tumor cells of the nervous system is not detectable with standardized pathologico-virological diagnostics".

Authors:  Charles Cobbs
Journal:  Neuro Oncol       Date:  2014-10-13       Impact factor: 12.300

Review 3.  Cytomegalovirus and glioblastoma; controversies and opportunities.

Authors:  Sean E Lawler
Journal:  J Neurooncol       Date:  2015-02-15       Impact factor: 4.130

4.  Provocative Question: Should Ketogenic Metabolic Therapy Become the Standard of Care for Glioblastoma?

Authors:  Thomas N Seyfried; Laura Shelton; Gabriel Arismendi-Morillo; Miriam Kalamian; Ahmed Elsakka; Joseph Maroon; Purna Mukherjee
Journal:  Neurochem Res       Date:  2019-04-25       Impact factor: 3.996

5.  Cytomegalovirus promotes murine glioblastoma growth via pericyte recruitment and angiogenesis.

Authors:  Harald Krenzlin; Prajna Behera; Viola Lorenz; Carmela Passaro; Mykola Zdioruk; Michal O Nowicki; Korneel Grauwet; Hong Zhang; Magdalena Skubal; Hirotaka Ito; Rachel Zane; Michael Gutknecht; Marion B Griessl; Franz Ricklefs; Lai Ding; Sharon Peled; Arun Rooj; C David James; Charles S Cobbs; Charles H Cook; E Antonio Chiocca; Sean E Lawler
Journal:  J Clin Invest       Date:  2019-03-11       Impact factor: 14.808

6.  Discordant humoral and cellular immune responses to Cytomegalovirus (CMV) in glioblastoma patients whose tumors are positive for CMV.

Authors:  Afsar Rahbar; Inti Peredo; Nina Wolmer Solberg; Chato Taher; Mensur Dzabic; Xinling Xu; Petra Skarman; Olesja Fornara; Charlotte Tammik; Koon Yaiw; Vanessa Wilhelmi; Alice Assinger; Giuseppe Stragliotto; Cecilia Söderberg-Naucler
Journal:  Oncoimmunology       Date:  2015-02-25       Impact factor: 8.110

7.  Cytomegalovirus infection induces a stem cell phenotype in human primary glioblastoma cells: prognostic significance and biological impact.

Authors:  O Fornara; J Bartek; A Rahbar; J Odeberg; Z Khan; I Peredo; P Hamerlik; J Bartek; G Stragliotto; N Landázuri; C Söderberg-Nauclér
Journal:  Cell Death Differ       Date:  2015-07-03       Impact factor: 15.828

8.  Cancer cell stemness, responses to experimental genotoxic treatments, cytomegalovirus protein expression and DNA replication stress in pediatric medulloblastomas.

Authors:  Jiri Bartek; Joanna M Merchut-Maya; Apolinar Maya-Mendoza; Olesja Fornara; Afsar Rahbar; Christian Beltoft Bröchner; Astrid Sehested; Cecilia Söderberg-Nauclér; Jiri Bartek; Jirina Bartkova
Journal:  Cell Cycle       Date:  2020-02-13       Impact factor: 4.534

9.  Murine Cytomegalovirus Infection of Melanoma Lesions Delays Tumor Growth by Recruiting and Repolarizing Monocytic Phagocytes in the Tumor.

Authors:  Nicole A Wilski; Christina Del Casale; Timothy J Purwin; Andrew E Aplin; Christopher M Snyder
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

10.  Poor survival in glioblastoma patients is associated with early signs of immunosenescence in the CD4 T-cell compartment after surgery.

Authors:  Olesja Fornara; Jenny Odeberg; Nina Wolmer Solberg; Charlotte Tammik; Petra Skarman; Inti Peredo; Giuseppe Stragliotto; Afsar Rahbar; Cecilia Söderberg-Nauclér
Journal:  Oncoimmunology       Date:  2015-06-05       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.